Nacuity Pharmaceuticals, Inc. was formed to focus on bringing a potential treatment with NACA to patients with RP (Retinitis Pigmentosa) guided by the groundbreaking work of Dr. Peter Campochiaro, MD, at the Wilmer Institute of Johns Hopkins University.
